{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:07Z","timestamp":1786979827174,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00228-024-03668-8","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T12:56:35Z","timestamp":1710334595000},"page":"941-947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-6748","authenticated-orcid":false,"given":"Mustafa","family":"Korkmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-5931","authenticated-orcid":false,"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-7964","authenticated-orcid":false,"given":"Mehmet Zahid","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-0295","authenticated-orcid":false,"given":"Muhammed Muhiddin","family":"Er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-4733","authenticated-orcid":false,"given":"Engin","family":"Hendem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-4695","authenticated-orcid":false,"given":"Aykut","family":"Demirk\u0131ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-9501","authenticated-orcid":false,"given":"Murat","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"issue":"1","key":"3668_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KA, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA A Cancer J Clin 73(1):17\u201348","journal-title":"CA A Cancer J Clin"},{"key":"3668_CR2","unstructured":"Garfield K, LaGrange CA (2024) Renal Cell Cancer. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing"},{"issue":"3","key":"3668_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A (2020) Epidemiology of renal cell carcinoma. World J Oncol 11(3):79\u201387","journal-title":"World J Oncol"},{"issue":"1","key":"3668_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","volume":"23","author":"DF McDermott","year":"2005","unstructured":"McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous \u0131nterleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133\u2013141","journal-title":"J Clin Oncol"},{"issue":"8","key":"3668_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722\u2013731","journal-title":"N Engl J Med"},{"issue":"10","key":"3668_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons M, Gordon E, Claesson-Welsh L (2016) Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 17(10):611\u2013625","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"3668_CR7","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","volume":"14","author":"N Steeghs","year":"2008","unstructured":"Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens MMC, Putter H, Rabelink TJ, De Koning EJ (2008) Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis \u0131nhibitor. Clin Cancer Res 14(11):3470\u20133476","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3668_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","volume":"23","author":"BI Rini","year":"2005","unstructured":"Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor\u2013targeted therapy in renal cell carcinoma. J Clin Oncol 23(5):1028\u20131043","journal-title":"J Clin Oncol"},{"issue":"9","key":"3668_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen D, Lu DR, Chen I, Hariharan S, Gore M, Figlin RA, Baum MJ, Motzer RJ (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763\u2013773","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"3668_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc2152","volume":"7","author":"HM Verheul","year":"2007","unstructured":"Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7(6):475\u2013485","journal-title":"Nat Rev Cancer"},{"key":"3668_CR11","doi-asserted-by":"publisher","first-page":"810262","DOI":"10.3389\/fcvm.2022.810262","volume":"9","author":"Z Ba","year":"2022","unstructured":"Ba Z, Xiao Y, He M, Liu D, Wang H, Liang H, Yuan J (2022) Risk factors for the comorbidity of hypertension and renal cell carcinoma in the cardio-oncologic era and treatment for tumor-induced hypertension. Front Cardiovasc Med 9:810262","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3668_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2125.2011.03980.x","volume":"72","author":"S Shah","year":"2011","unstructured":"Shah S, Harris T, Owen CG, DeWilde S, Cook DG (2011) Does \u03b2-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 72(1):157\u2013161","journal-title":"Br J Clin Pharmacol"},{"key":"3668_CR13","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.2147\/OTT.S167422","volume":"11","author":"Z Na","year":"2018","unstructured":"Na Z, Qiao X, Hao X, Fan L, Xiao Y, Shao Y, Sun M, Feng Z, Guo W, Li J, Li J, Li D (2018) The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients. Onco Targets Ther 11:4913\u20134944","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3668_CR14","doi-asserted-by":"publisher","first-page":"36.e1","DOI":"10.1016\/j.urolonc.2016.08.013","volume":"35","author":"W Parker","year":"2017","unstructured":"Parker W, Lohse CM, Zaid HB, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH (2017) Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. Urologic Oncology-seminars and Original Investigations 35(1):36.e1-36","journal-title":"Urologic Oncology-seminars and Original Investigations"},{"issue":"7","key":"3668_CR15","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00432-019-02914-2","volume":"145","author":"E Neumann","year":"2019","unstructured":"Neumann E, Klaiber P, Freitag K, Schwab M, Schaeffeler E, Hennenlotter J, Fend F, Kruck S, Scharpf M, Stenzl A, Bedke J, Rausch S (2019) Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. J Cancer Res Clin Oncol 145(7):1835\u20131843","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"3668_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.17219\/acem\/84800","volume":"27","author":"L Babiak-Choroszczak","year":"2018","unstructured":"Babiak-Choroszczak L, Gi\u017cewska-Kacprzak K, Gawrych E, Fischer K, Walecka A, Puchalska-Niedba\u0142 L, Rajewska-Majchrzak J, Bag\u0142aj M (2018) Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: are we closer to understand the mechanism of action of propranolol on hemangiomas? Adv Clin Exp Med 27(5):703\u2013710","journal-title":"Adv Clin Exp Med"},{"issue":"46","key":"3668_CR17","doi-asserted-by":"publisher","first-page":"35462","DOI":"10.1074\/jbc.M110.109579","volume":"285","author":"MM Shahzad","year":"2010","unstructured":"Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee J, Jennings NR, Bottsford-Miller J, Vivas-Mejia PE, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK (2010) Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 285(46):35462\u201335470","journal-title":"J Biol Chem"},{"issue":"5","key":"3668_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","volume":"25","author":"S Zhong","year":"2016","unstructured":"Zhong S, Yu D, Zhang X, Chen X, Yang S, Tang J, Zhao J, Wang S (2016) \u03b2-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Eur J Cancer Prev 25(5):440\u2013448","journal-title":"Eur J Cancer Prev"},{"issue":"4","key":"3668_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00228-023-03464-w","volume":"79","author":"MZ Kocak","year":"2023","unstructured":"Kocak MZ, Er M, Ugrakli M, Hendem E, Araz M, Eryilmaz MK, Artac M (2023) Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer? Eur J Clin Pharmacol 79(4):485\u2013491","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"3668_CR20","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers11121856","volume":"11","author":"O Fiala","year":"2019","unstructured":"Fiala O, Ostasov P, Sorejs O, Liska V, Buchler T, Poprach A, Finek J (2019) Incidental use of beta-blockers \u0131s associated with outcome of metastatic colorectal cancer patients treated with bevacizumab-based therapy: a single-\u0131nstitution retrospective analysis of 514 patients. Cancers 11(12):1856","journal-title":"Cancers"},{"issue":"24","key":"3668_CR21","doi-asserted-by":"publisher","first-page":"e719","DOI":"10.1097\/MD.0000000000000719","volume":"94","author":"R Giampieri","year":"2015","unstructured":"Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, Ridolfi F, Cascinu S (2015) Prognostic value for incidental antihypertensive therapy with \u03b2-blockers in metastatic colorectal cancer. Med 94(24):e719","journal-title":"Med"},{"issue":"5","key":"3668_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11523-021-00829-y","volume":"16","author":"O Fiala","year":"2021","unstructured":"Fiala O, Ostasov P, Rozsypalova A, Hora M, \u0160orejs O, \u0160ustr J, Bendov\u00e1 B, Tr\u00e1vn\u00ed\u010dek I, Filipovsk\u00fd J, F\u00ednek J, Buchler T (2021) Impact of concomitant cardiovascular medication on survival of metastatic renal cell carcinoma patients treated with sunitinib or pazopanib in the first line. Target Oncol 16(5):643\u2013652","journal-title":"Target Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03668-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T03:05:40Z","timestamp":1715828740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03668-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3668"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03668-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"12 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Ethics Committee of Necmettin Erbakan University (approval no: 2021\/3560).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was not obtained as the study was a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}